Neurology

Due to the observational nature of the study, the study authors said they cannot determine causal relationships between statins and cognitive decline for patients with Alzheimer disease.

From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.

Investigators analyzed the effects of harmful accumulation of HDAC6 in the brains of mouse models with Alzheimer disease to determine any changes in disease progression.

Improvements in PFS were also seen among patients with brain metastases.

Patients with this genetic variant have impaired neuronal excitability, a trait that has been linked to malfunctional synapses.

Following acoustic stimulation intervention, many patients experienced a reduction in neurobehavioral symptoms.

Drug reaction with eosinophilia and systemic symptoms can start as a rash and quickly progress, affecting the internal organs and requiring hospitalization, even resulting in death.

Lisa Deschamps, CEO of AviadoBio, discusses frontotemporal dementia and AVB-101, a one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene and restoring progranulin levels in the brain.

More studies are needed to show conclusive benefits on patient functionality.

Pharmacists can play a vital role in educating patients about headaches and can help to limit their impact on the patient.

Improvements in AI could change the way pharmacists and providers interact with, and care for, patients.

Pharmacists play a key role in optimizing drug therapy according to the most updated guidelines, educating patients or prescribers, and monitoring therapeutic outcomes.

A weekly dose of injectable lecanemab-irmb (Leqembi) could allow patients with Alzheimer disease to receive the drug at home instead of visiting an infusion center twice per month.

In the clinical setting, psychedelic medicine has promise as a safe and efficacious treatment for PTSD, TBIs, and other mental health issues.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody that targets amyloid plaques, which are thought to play a role in the development and progression of Alzheimer disease.

A subcutaneous injection of ocrelizumab was markedly effective at suppressing brain lesions in patients with multiple sclerosis, according to data from a phase 3 trial.

Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.

Choice of therapy should be selected based on patient needs and conditions.

Intravenous immunoglobulin found to provide fast and long-lasting relief for COVID-19-related neurological conditions, although investigators are still uncovering the pathology of many of these conditions.

This disease can, at the very least, help researchers to “identify” the floodgates to definitive tests and therapies for complex psychological and neurological diseases, expert says.

In clinical trials, lecanemab showed a reduction of amyloid beta plaque in patients with Alzheimer disease.

Testosterone may protect the brain against dementia pathology, but the association has not been proven.

Infections were associated with a 1.49-fold increase in the rate of dementia in both the short- and long-term rates, however, the increases were greater in the short term.

Symptoms of dementia can be difficult to differentiate from typical age-related behavior changes and other common and potentially curable conditions.

One IVIG product showed overall improvement in neuroprotection, including alleviating cognitive decline and ameliorating AB deposition in Alzheimer disease.